BACKGROUND: This report examines the association between race and vincristine-associated neurotoxicity in pediatric patients with precursor B cell acute lymphoblastic leukemia (preB ALL). Given that in vitro vincristine is metabolized more efficiently by cytochrome P450 (CYP) 3A5 than by CYP3A4 and that 70% African-Americans (vs. 20% of Caucasians) express CYP3A5, one may hypothesize that African-Americans metabolize vincristine more efficiently resulting in lower vincristine exposure and associated-toxicity. PROCEDURE: A retrospective analysis of vincristine-related side effects in pediatric patients treated for preB ALL was performed. Data were compared between Caucasians (n = 92) and African-Americans (n = 21) to examine the relationship between race and vincristine-associated neurotoxicity thus using race as a surrogate for CYP3A5 genotype. Race, age, gender, disease subtype, highest grade of vincristine-associated neurotoxicity (per NIH Common Terminology Criteria for Adverse Events version 3.0), number of omitted and reduced vincristine doses, cumulative vincristine dose, and disease outcome were captured. RESULTS: 34.8% of Caucasians experienced symptoms consistent with vincristine-related neurotoxicity compared to 4.8% of African-Americans (P = 0.007). The average grade of neurotoxicity for Caucasians was 2.72 versus grade 1 neurotoxicity in the African-American (P < 0.0001). Four percent of total doses administered to Caucasian patients were reduced due to vincristine-related neurotoxicity compared to 0.1% given to African-Americans (P < 0.0001). 1.2% of all protocol-indicated doses for Caucasians were held due to severe vincristine-associated toxicity compared to 0.1% of doses for African-Americans (P < 0.01). CONCLUSIONS: The data support the hypothesis pharmacogenetic polymorphisms in CYP3A5 expression contribute to variability in vincristine metabolism and neurotoxicity. (c) 2008 Wiley-Liss, Inc.
BACKGROUND: This report examines the association between race and vincristine-associated neurotoxicity in pediatric patients with precursor B cell acute lymphoblastic leukemia (preB ALL). Given that in vitro vincristine is metabolized more efficiently by cytochrome P450 (CYP) 3A5 than by CYP3A4 and that 70% African-Americans (vs. 20% of Caucasians) express CYP3A5, one may hypothesize that African-Americans metabolize vincristine more efficiently resulting in lower vincristine exposure and associated-toxicity. PROCEDURE: A retrospective analysis of vincristine-related side effects in pediatric patients treated for preB ALL was performed. Data were compared between Caucasians (n = 92) and African-Americans (n = 21) to examine the relationship between race and vincristine-associated neurotoxicity thus using race as a surrogate for CYP3A5 genotype. Race, age, gender, disease subtype, highest grade of vincristine-associated neurotoxicity (per NIH Common Terminology Criteria for Adverse Events version 3.0), number of omitted and reduced vincristine doses, cumulative vincristine dose, and disease outcome were captured. RESULTS: 34.8% of Caucasians experienced symptoms consistent with vincristine-related neurotoxicity compared to 4.8% of African-Americans (P = 0.007). The average grade of neurotoxicity for Caucasians was 2.72 versus grade 1 neurotoxicity in the African-American (P < 0.0001). Four percent of total doses administered to Caucasian patients were reduced due to vincristine-related neurotoxicity compared to 0.1% given to African-Americans (P < 0.0001). 1.2% of all protocol-indicated doses for Caucasians were held due to severe vincristine-associated toxicity compared to 0.1% of doses for African-Americans (P < 0.01). CONCLUSIONS: The data support the hypothesis pharmacogenetic polymorphisms in CYP3A5 expression contribute to variability in vincristine metabolism and neurotoxicity. (c) 2008 Wiley-Liss, Inc.
Authors: Lang Li; Tammy Sajdyk; Ellen M L Smith; Chien Wei Chang; Claire Li; Richard H Ho; Raymond Hutchinson; Elizabeth Wells; Jodi L Skiles; Naomi Winick; Paul L Martin; Jamie L Renbarger Journal: Clin Pharmacol Ther Date: 2019-01-21 Impact factor: 6.875
Authors: Bryan Langholz; Jeffrey M Skolnik; Jeffrey S Barrett; Jamie Renbarger; Nita L Seibel; Anne Zajicek; Carola A S Arndt Journal: Pediatr Blood Cancer Date: 2010-12-01 Impact factor: 3.167
Authors: Akinbode Egbelakin; Michael J Ferguson; Emily A MacGill; Amalia S Lehmann; Ariel R Topletz; Sara K Quinney; Lang Li; Kevin C McCammack; Stephen D Hall; Jamie L Renbarger Journal: Pediatr Blood Cancer Date: 2010-11-11 Impact factor: 3.167
Authors: F Aminkeng; C J D Ross; S R Rassekh; L R Brunham; J Sistonen; M-P Dube; M Ibrahim; T B Nyambo; S A Omar; A Froment; J-M Bodo; S Tishkoff; B C Carleton; M R Hayden Journal: Pharmacogenomics J Date: 2013-04-16 Impact factor: 3.550
Authors: James W Behan; Vassilios I Avramis; Jason P Yun; Stan G Louie; Steven D Mittelman Journal: Pharmacol Res Date: 2010-01-18 Impact factor: 7.658